U.S. Specialized REITs Stock News

Altria Group (MO) moved back into focus after its late July Q2 2026 earnings release, which combined a revenue beat with an earnings miss and a tighter full year adjusted EPS outlook. See our latest analysis for Altria Group. The mixed Q2 2026 earnings picture and ongoing share buybacks appear to be key drivers behind Altria Group's recent moves, with the share price at US$68.35 after a 19.26% year to date share price return and a 5 year total shareholder return of 106.98%. This suggests...

Tilray Brands (TLRY) just rolled out Mollo Lite Blackberry Lemon Seltzers as its first light THC beverage multipack in Canada, putting fresh attention on how the stock reflects its cannabis beverage platform. See our latest analysis for Tilray Brands. The new Mollo Lite launch lands after a mixed run for Tilray Brands, with a 1-day share price return of 2.93% to US$4.57 and a 30-day share price return of 4.10%, but a year-to-date share price decline of 52.98% and a 5-year total shareholder...

Earnings and Guidance Update Put CONMED Stock in Focus CONMED (CNMD) drew fresh attention after reporting second quarter 2026 results, with net income and earnings per share higher than a year earlier and a modestly raised full year net sales outlook. See our latest analysis for CONMED. The latest earnings and modest guidance lift have come alongside a sharp shift in sentiment, with CONMED’s share price up 46.23% over the past month. However, the 1 year total shareholder return is still down...

What LivaNova’s latest earnings mean for the stock now LivaNova (NasdaqGS:LIVN) released second quarter 2026 results that showed higher sales and a shift from last year’s loss to net income, which quickly put the stock back on many investors’ radars. See our latest analysis for LivaNova. LivaNova’s strong second quarter has landed on top of a share price that is now US$76.22, with a 1 year to date share price return of 25.69% and a 1 year total shareholder return of 56.06%, suggesting...

Buckle (BKE) shares are in focus after the retailer reported higher comparable store net sales and total net sales across the latest 4-week, second-quarter, and year-to-date periods. See our latest analysis for Buckle. The trading update appears to have shifted sentiment around Buckle, with the share price up 10.81% over the past month but still down 14.70% year to date on a share price return basis. The 5 year total shareholder return of 71.46% shows the longer term picture. If Buckle’s...

In the second quarter of 2026, Tronox Holdings plc reported sales of US$868 million, up from US$731 million a year earlier, while its net loss widened to US$171 million and the Board maintained a US$0.05 quarterly dividend. The company’s guidance for a mid-single-digit moderation in third-quarter production volumes and the appointment of audit veteran Keith Schwarz to the Board highlight a focus on managing seasonal demand patterns while reinforcing financial oversight amid ongoing...

Kulicke and Soffa Industries (KLIC) stock is back in focus after the company reported strong third quarter results, issued higher revenue and earnings guidance, and confirmed progress on capacity expansion in key advanced packaging areas. See our latest analysis for Kulicke and Soffa Industries. Against this backdrop, Kulicke and Soffa Industries’ recent earnings beat and higher guidance have come after a sharp reset. The 30 day share price return is 12.4% and the 90 day share price return is...

CME Group recently declared a third-quarter dividend of US$1.30 per share, payable on 25 September 2026 to shareholders of record on 9 September 2026, and has been expanding its derivatives lineup with launches such as E-nano equity index futures and new sports-related benchmarks through its partnership with FutureSports LLC. Together with growing adoption of smaller-sized contracts like Spot-Quoted futures and record trading activity in key currency products, these moves highlight CME...

Bio-Rad Laboratories stock has rebounded in the short term, yet the current price around US$352 still screens as expensive relative to its intrinsic value estimate and market multiples. After a 5 year period where the share price fell 54.7%, the recent strength sits against valuation checks that point to a premium rather than a clear bargain. Over the last 5 years, Bio-Rad Laboratories is down 54.7%, which suggests long term holders have taken a significant hit even though the recent share...

With the June 2026 CPI print landing just weeks before a key Federal Reserve meeting, interest rate expectations are again front and center for anyone watching US real estate stocks. Rate sensitive property companies can see their borrowing costs and valuations shift quickly when inflation surprises. This article breaks down how that backdrop connects to three stocks from a US Rate Sensitive Real Estate screener and why their reactions could matter for your portfolio. The three stocks below...

Thermo Fisher Scientific event puts specialty diagnostics in focus Thermo Fisher Scientific (TMO) has put its specialty diagnostics business in the spotlight after showcasing new products and recent U.S. Food and Drug Administration clearances at the ADLM conference in Anaheim in late July 2026. The event highlighted the EXENT Solution for multiple myeloma monitoring and the EliA CTD 13 Screen for autoimmune disease testing, along with software and quality control tools designed to support...

In early August 2026, State Street Corporation amended its Articles of Organization in Massachusetts to codify the terms of its new Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series L, including its US$100,000 per share liquidation preference and placement alongside other preferred series. This legal update followed the completion of a US$500 million offering of perpetual, callable, non-cumulative preferred depositary shares, highlighting an ongoing reshaping of State...

In early August 2026, Varonis Systems, Inc. launched Agent Intent-Based Access Control within its Atlas platform, adding safeguards that monitor AI agents’ reasoning, tool use, and data access, while also reporting second-quarter revenue of US$180.02 million and updated guidance for continued double-digit revenue growth in 2026. This combination of advanced controls for AI agent behavior and a reinforced growth outlook highlights how Varonis is aligning its data security platform with...

Worthington Enterprises stock snapshot after recent trading move Worthington Enterprises (WOR) has drawn investor attention after a recent trading move, with the stock last closing at $58.42. That price comes alongside a value score of 5 and an intrinsic discount of 36.9%. See our latest analysis for Worthington Enterprises. Recent trading fits into a broader picture for Worthington Enterprises, with a 30 day share price return of 10.69% and a year to date share price return of 12.43%. This...

Recent commentary on AGNC Investment Corp. highlights that the mortgage REIT is trading at roughly a 25% premium to its Q2 2026 tangible net book value per share of US$8.58, while its double‑digit dividend yield currently appears supported by net spread income. However, concerns about how rising interest rates, leverage, and macroeconomic pressures could affect the sustainability of that high payout are now a central focus for investors assessing AGNC’s risk profile. We’ll now examine how...

Retirement has quietly entered a new phase. Instead of shifting almost everything into cash and bonds at age 65, many investors are being encouraged to keep 40% to 80% in equities to help manage inflation and longer lifespans. As a result, a larger share of retirement money could flow toward certain stocks and funds, while others may see less attention. This article examines three stocks from our Retirement Income Growth Stocks With Equity Allocation Tailwinds screener that stand out as...

MannKind Corporation recently reported its second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier while moving from a small net profit to a net loss of US$19.03 million. A few days earlier, MannKind released positive Phase 1b data for its inhaled nintedanib in idiopathic pulmonary fibrosis, underscoring the potential of its Technosphere platform to extend into high-need lung indications beyond its current commercial products. We’ll now...

Spotify Technology has fallen sharply over the past year but still screens as attractively priced on Simply Wall St's intrinsic value checks, with the Discounted Cash Flow (DCF) estimate pointing to a meaningful gap to the current share price even as market multiples suggest the stock is closer to fair. Spotify Technology has returned about 252% over the past 3 years, which means investors are now weighing a strong multi year run against whether the current price still offers enough...

Structure Therapeutics recently advanced its obesity portfolio by dosing the first patients in its Phase 3 ACCOMPLISH trial of oral aleniglipron and appointing veteran commercial leader John Berrios as Chief Commercial Officer. The combination of late-stage trial progress and leadership drawn from major obesity and diabetes franchises highlights Structure’s focus on preparing aleniglipron for potential large-scale commercialization. Next, we’ll examine how the Phase 3 launch of aleniglipron...

UroGen Pharma stock has delivered very strong share price returns over the past five years, yet its current valuation checks and market multiples now suggest the shares are closer to fairly priced than a clear bargain. UroGen Pharma has returned about 210% over the last 5 years, which puts recent gains front and center when judging whether the current price already reflects much of that success. Expectations around UroGen Pharma’s ability to grow revenue and eventually convert its pipeline...

Berkshire Hathaway’s renewed buying spree under Greg Abel, including a US$10b move into Alphabet and billions more in equities, has turned a quiet market narrative into something far more exciting for stock pickers. When a giant like Berkshire starts writing big checks again, many investors worry about missing the next wave of opportunity. This article looks at three stocks tied to that shift and how this renewed confidence could matter for your portfolio decisions. Berkshire Hathaway...

Global Partners (GLP) is back on investor radar after reporting second quarter 2026 results, with higher sales, net income, earnings per unit, and a recent cash distribution announcement drawing fresh attention to the stock. See our latest analysis for Global Partners. The latest earnings release and July cash distribution decision have arrived alongside a solid share price trend for Global Partners, with the stock up 18.74% year to date on a share price return basis and a 5.09% total...

Meta Platforms stock has pulled back this year even though the valuation work still leans positive, with the Discounted Cash Flow (DCF) intrinsic value estimate and earnings based multiples both pointing to an undervalued share price relative to those fundamentals. Meta Platforms has returned about 98% over the past 3 years, which means many investors are now asking whether the recent share price leaves enough room for further value to be realised. Heavy investment in AI infrastructure and...

In late July 2026, InterDigital, Inc. reported that second-quarter sales fell to US$260.17 million and net income to US$116.37 million, yet also updated investors on ongoing share repurchases. Despite weaker quarterly results, the company raised its full-year 2026 revenue and earnings guidance, signaling management confidence in a stronger second half. Next, we’ll examine how InterDigital’s upgraded full-year 2026 guidance reshapes the existing investment narrative around its earnings...